TMEM139 prevents NSCLC metastasis by inhibiting lysosomal degradation of E-cadherin

Cancer Sci. 2022 Jun;113(6):1999-2007. doi: 10.1111/cas.15341. Epub 2022 Apr 1.

Abstract

Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and has the highest mortality rate among all solid tumors. It is characterized by early metastasis, and investigations of the molecular mechanisms underlying the progression and metastasis of NSCLC are urgently needed for the development of therapeutic targets. Here, we report that the transmembrane protein TMEM139 is significantly downregulated in NSCLC and that reduced expression of TMEM139 is correlated with a poor prognosis in NSCLC patients. Mechanistically, we found that TMEM139 directly interacts with E-cadherin at the plasma membrane and at focal adhesion sites. Moreover, TMEM139 can prevent the lysosomal degradation of E-cadherin, which inhibits epithelial-mesenchymal transition, migration and invasion of NSCLC cells both in vitro and in vivo. Our study not only expands our understanding of NSCLC metastasis but also provides a foundation to develop novel therapeutic strategies.

Keywords: E-cadherin; TMEM139; epithelial-mesenchymal transition; lysosomal degradation; non-small-cell lung cancer.

MeSH terms

  • Antigens, CD
  • Cadherins* / metabolism
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Cell Line, Tumor
  • Cell Movement
  • Epithelial-Mesenchymal Transition
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms* / pathology
  • Lysosomes / metabolism
  • Membrane Proteins* / genetics
  • Neoplasm Invasiveness / pathology
  • Neoplasm Metastasis / pathology

Substances

  • Antigens, CD
  • CDH1 protein, human
  • Cadherins
  • Membrane Proteins
  • TMEM139 protein, human